SHPG has been the subject of a number of other reports. Cowen set a $225.00 price target on Shire and gave the stock a buy rating in a report on Friday, January 5th. Zacks Investment Research raised Shire from a sell rating to a hold rating in a report on Friday, October 27th. Cantor Fitzgerald reaffirmed a buy rating and set a $222.00 price target on shares of Shire in a report on Friday, October 27th. Liberum Capital raised Shire from a hold rating to a buy rating in a report on Tuesday, November 14th. Finally, ValuEngine raised Shire from a hold rating to a buy rating in a report on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $204.00.
Shire (SHPG) traded up $1.34 during trading hours on Tuesday, reaching $132.56. The company had a trading volume of 524,401 shares, compared to its average volume of 1,270,000. The stock has a market capitalization of $40,130.00, a price-to-earnings ratio of 21.84, a PEG ratio of 0.77 and a beta of 1.43. Shire has a 52-week low of $123.73 and a 52-week high of $192.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.55 and a current ratio of 0.97.
Shire (NASDAQ:SHPG) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.86 by $0.12. The firm had revenue of $4.14 billion during the quarter. Shire had a return on equity of 14.19% and a net margin of 28.17%. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter last year, the business posted $3.37 earnings per share. equities analysts anticipate that Shire will post 15.23 earnings per share for the current fiscal year.
The company also recently announced a semiannual dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Friday, March 9th will be issued a $0.8937 dividend. This is an increase from Shire’s previous semiannual dividend of $0.15. This represents a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. Shire’s payout ratio is presently 17.30%.
Several institutional investors have recently bought and sold shares of SHPG. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Shire by 6.2% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock valued at $1,073,000 after purchasing an additional 381 shares during the last quarter. Sterling Capital Management LLC purchased a new stake in shares of Shire in the 2nd quarter valued at about $299,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Shire in the 2nd quarter valued at about $406,000. Fisher Asset Management LLC lifted its holdings in shares of Shire by 2.9% in the 3rd quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock valued at $8,793,000 after purchasing an additional 1,619 shares during the last quarter. Finally, Osborne Partners Capital Management LLC lifted its holdings in shares of Shire by 5.2% in the 3rd quarter. Osborne Partners Capital Management LLC now owns 38,500 shares of the biopharmaceutical company’s stock valued at $5,896,000 after purchasing an additional 1,905 shares during the last quarter. 19.75% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://ledgergazette.com/2018/03/15/shires-shpg-neutral-rating-reiterated-at-jpmorgan-chase-co.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.